BRPI0707239A8 - peptídeo de ligação de fgf2, peptídeo quimérico fundido ou conjugado, molécula de ácido nucléico, vetor de expressão, célula hospedeira e composição farmacêutica - Google Patents
peptídeo de ligação de fgf2, peptídeo quimérico fundido ou conjugado, molécula de ácido nucléico, vetor de expressão, célula hospedeira e composição farmacêuticaInfo
- Publication number
- BRPI0707239A8 BRPI0707239A8 BRPI0707239A BRPI0707239A BRPI0707239A8 BR PI0707239 A8 BRPI0707239 A8 BR PI0707239A8 BR PI0707239 A BRPI0707239 A BR PI0707239A BR PI0707239 A BRPI0707239 A BR PI0707239A BR PI0707239 A8 BRPI0707239 A8 BR PI0707239A8
- Authority
- BR
- Brazil
- Prior art keywords
- fused
- nucleic acid
- peptide
- pharmaceutical composition
- host cell
- Prior art date
Links
- 101150019331 FGF2 gene Proteins 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- YSFTYXKQUONNFY-NQXPEFQPSA-N fgf2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 title abstract 3
- 108091006116 chimeric peptides Proteins 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 230000003466 anti-cipated effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 230000001023 pro-angiogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06001457 | 2006-01-24 | ||
| EP06001457.8 | 2006-01-24 | ||
| PCT/EP2007/000538 WO2007085412A1 (en) | 2006-01-24 | 2007-01-23 | Fgf2-binding peptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0707239A2 BRPI0707239A2 (pt) | 2011-04-26 |
| BRPI0707239A8 true BRPI0707239A8 (pt) | 2018-01-30 |
Family
ID=37421191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0707239A BRPI0707239A8 (pt) | 2006-01-24 | 2007-01-23 | peptídeo de ligação de fgf2, peptídeo quimérico fundido ou conjugado, molécula de ácido nucléico, vetor de expressão, célula hospedeira e composição farmacêutica |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8076300B2 (enExample) |
| EP (1) | EP1973944B1 (enExample) |
| JP (1) | JP5427415B2 (enExample) |
| KR (1) | KR101467453B1 (enExample) |
| CN (1) | CN101384622B (enExample) |
| AU (1) | AU2007209581B2 (enExample) |
| BR (1) | BRPI0707239A8 (enExample) |
| CA (1) | CA2637295C (enExample) |
| DK (1) | DK1973944T3 (enExample) |
| EA (1) | EA015339B1 (enExample) |
| ES (1) | ES2575517T3 (enExample) |
| HR (1) | HRP20160600T1 (enExample) |
| HU (1) | HUE029212T2 (enExample) |
| IL (1) | IL192800A (enExample) |
| MX (1) | MX2008009289A (enExample) |
| PL (1) | PL1973944T3 (enExample) |
| PT (1) | PT1973944T (enExample) |
| SI (1) | SI1973944T1 (enExample) |
| WO (1) | WO2007085412A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831622B (zh) | 2017-05-05 | 2023-06-20 | 德克萨斯大学系统董事会 | Fgl2单克隆抗体及其在治疗恶性肿瘤中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
-
2007
- 2007-01-23 EA EA200870188A patent/EA015339B1/ru not_active IP Right Cessation
- 2007-01-23 HU HUE07702949A patent/HUE029212T2/en unknown
- 2007-01-23 BR BRPI0707239A patent/BRPI0707239A8/pt not_active IP Right Cessation
- 2007-01-23 MX MX2008009289A patent/MX2008009289A/es active IP Right Grant
- 2007-01-23 JP JP2008551712A patent/JP5427415B2/ja not_active Expired - Fee Related
- 2007-01-23 SI SI200731788A patent/SI1973944T1/sl unknown
- 2007-01-23 US US12/161,950 patent/US8076300B2/en not_active Expired - Fee Related
- 2007-01-23 ES ES07702949.4T patent/ES2575517T3/es active Active
- 2007-01-23 AU AU2007209581A patent/AU2007209581B2/en not_active Ceased
- 2007-01-23 PL PL07702949.4T patent/PL1973944T3/pl unknown
- 2007-01-23 EP EP07702949.4A patent/EP1973944B1/en active Active
- 2007-01-23 CN CN2007800033499A patent/CN101384622B/zh not_active Expired - Fee Related
- 2007-01-23 CA CA2637295A patent/CA2637295C/en not_active Expired - Fee Related
- 2007-01-23 DK DK07702949.4T patent/DK1973944T3/en active
- 2007-01-23 WO PCT/EP2007/000538 patent/WO2007085412A1/en not_active Ceased
- 2007-01-23 PT PT77029494T patent/PT1973944T/pt unknown
- 2007-01-23 HR HRP20160600TT patent/HRP20160600T1/hr unknown
-
2008
- 2008-07-14 IL IL192800A patent/IL192800A/en not_active IP Right Cessation
- 2008-08-22 KR KR1020087020664A patent/KR101467453B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009523457A (ja) | 2009-06-25 |
| EA200870188A1 (ru) | 2009-02-27 |
| PL1973944T3 (pl) | 2016-09-30 |
| WO2007085412A1 (en) | 2007-08-02 |
| KR101467453B1 (ko) | 2014-12-01 |
| EA015339B1 (ru) | 2011-06-30 |
| MX2008009289A (es) | 2008-10-17 |
| AU2007209581A1 (en) | 2007-08-02 |
| SI1973944T1 (sl) | 2016-07-29 |
| CN101384622B (zh) | 2013-03-27 |
| CA2637295A1 (en) | 2007-08-02 |
| KR20080096794A (ko) | 2008-11-03 |
| WO2007085412B1 (en) | 2007-10-11 |
| PT1973944T (pt) | 2016-07-07 |
| IL192800A (en) | 2015-04-30 |
| BRPI0707239A2 (pt) | 2011-04-26 |
| HRP20160600T1 (hr) | 2016-07-01 |
| CA2637295C (en) | 2017-06-13 |
| EP1973944B1 (en) | 2016-05-11 |
| DK1973944T3 (en) | 2016-06-27 |
| JP5427415B2 (ja) | 2014-02-26 |
| CN101384622A (zh) | 2009-03-11 |
| US20090215689A1 (en) | 2009-08-27 |
| US8076300B2 (en) | 2011-12-13 |
| IL192800A0 (en) | 2009-02-11 |
| EP1973944A1 (en) | 2008-10-01 |
| AU2007209581B2 (en) | 2013-03-28 |
| HUE029212T2 (en) | 2017-02-28 |
| ES2575517T3 (es) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200325T1 (hr) | T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3 | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| PE20081140A1 (es) | Agentes terapeuticos a base de peptidos derivados de toxinas | |
| BRPI0807929A2 (pt) | Anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, polipeptídeo isolado, composição, ácido nucleico isolado, vetor de expressão, célula hospedeira, vacina do vírus da hepatite c (hcv), kit, métodos para tratar e detectar uma infecção por vírus da hepatite c (hcv) e para identificar um anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo, e, proteína e2 recombinante do vírus da hepatite c (hcv) | |
| RU2012151205A (ru) | Модифицированные связывающие белки, ингибирующие взаимодействие vegf-a рецептора | |
| IN2012DN02981A (enExample) | ||
| BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
| RU2015143057A (ru) | Гипергликозилированные связывающие полипептиды | |
| MX2022015847A (es) | Proteinas de union a cd123 y composiciones y metodos relacionados. | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| CO6470863A2 (es) | Mutantes fgf21 y usos de los mismos | |
| AR071874A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| WO2008070357A3 (en) | Smoothened polypeptides and methods of use | |
| WO2009004315A8 (en) | Isolated peptides and uses thereof | |
| BRPI0508935A (pt) | agonistas de receptor seletivo y4 para intervenções terapêuticas | |
| ATE517118T1 (de) | Bis-met-histone | |
| WO2010085700A3 (en) | Treatment for obesity | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
| NO20092697L (no) | Transportmolekyler ved bruk av revers-sekvens HIV-TAT polypeptider | |
| WO2009081374A3 (en) | Cosmetic use of plakoglobin-type proteins | |
| WO2012091564A3 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| WO2008093058A3 (en) | Peptides and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. ( |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2550 DE 19-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |